



1/1

Request form for non-invasive prenatal testing of aneuploidies - PRENASCAN

Personal data of the patient (label):	Referring physician:
Name and surname:	
Birth identification number/ID number:	
Date of birth:	
Insurance:	
Gender: Female	
Address:	
Diagnosis (ICD):	(name, specialisation, identification number, workplace, stamp, signature)
Primary sample:	
Peripheral blood (Streck Cell-Free DNA BCT CE, 10 ml non-coagulated blood)*	
*After blood collection, it is necessary to invert the tube 10 times and store it at room temperature. The blood must be delivered to the laboratory within 2-3 days of collection!	
·	Date and time of indication (if different from the collection data).
Date and time of collection:	Date and time of indication (if different from the collection date):
Clinical data: (to be completed by the referring physician)	
Vanishing twin syndrome:* YES NO Is it a repeated blood collection for this examination? YES NO	
*) If YES: The examination can be performed in the case of vanishing twin syndrome only if it has been diagnosed by the 8th week of pregnancy, and the sample collection	
follows at least 8 weeks after the cessation of development of the second foetus.	
Number of foetuses: ☐ 1 ☐ 2 → Is it: ☐ Monozygotic ☐ Dizygotic ☐ Zygosity undetermined	
Pregnancy after IVF: YES NO PGT was conducted: YES NO Donated Secretary Average NO Donor's age:	
oocyte:	
Weight (kg): Date of last menstruation:	
Height (cm): Gestational age at the time of collection Weeks: + Days: according to US: + Days:	
nisk 011211/	
Risk of T18 1/	
Risk of T13 1/	
Is the patient taking anticoagulants (heparin-based)? YES NO Number of hours since the last medication dose:*	
*) If the patient is taking anticoagulants (e.g., Fraxiparine, Clexane), there is a higher risk of an uninformative test result and the need for repeated collection. Blood collection must be done before the administration of the next dose of the medication (i.e., as far away as possible from the last dose).	
Results will be sent to the following doctor's email:	
Informed consent* – The patient has been provided with the consent form and instructions regarding PRENASCAN, and the patient agrees:	
With the examination of the sample Does the patient want to know	by the YES NO NO: We will not report the gender of the foetus, but
gender of the foetus?	we analyse sex chromosomes, and in the case of abnormalities in sex chromosomes, we will report
With the use of the sample for research purposes	this finding, including the gender of the foetus!
Does the natient want to know additional TYES TNO If YES: We a	nalyse the entire genome and report all findings of size 7Mb or larger. alyse only chromosomes 21, 13, and 18, and abnormalities of the sex chromosomes.
*) By submitting the request, the referring physician confirms that the patient or legal representative has signed the informed consent with the examination, which	
is either stored in the patient's documentation or attached to this request.	
The examination is conducted by: GENNET, s. r. o., Laboratories GENNET, Pekařská 635/6, 158 00 Prague 5 – Jinonice, Tel: 226 231 691	
Laboratory notes:	
Date and time of sample/request reception: Sample/request was received by:	

